- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00744731
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
June 10, 2013 updated by: SK Life Science, Inc.
The Open Label Extension Portion of the Study Entitled A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.
The purpose of this study is to obtain long-term safety and tolerability information on carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.
Seizure counts will be obtained to measure the rate of seizures for each patient during the study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
CARISEPY3014 is the open-label extension study that follows the double-blind study CARISEPY3013 (NCT00740623).
In an open label study such as CARISEPY3014, both the physician and the patient know the name of the assigned study medication.
In a double blind study such as CARISEPY-3013, neither the physician nor the patient knows the name of the assigned study medication.
Patients who complete the 14-week double-blind treatment phase of study CARISEPY3013 will be eligible to enter the open-label extension study during which patients will transition through a 1-week blinded period to open-label carisbamate.
There will be a 1 week blinded transition during which patients will take blinded study medication; after this, patients will then take unblinded, open-label study medication.
Safety assessments include the monitoring of the frequency, severity, and timing of adverse events, clinical laboratory test results, 12-lead electrocardiogram (ECG) recordings, vital signs measurements, physical and neurologic examinations, the Physician Withdrawal Checklist for symptoms of withdrawal for those patients who taper and/or discontinue study drug, and pregnancy tests for females of childbearing potential.
Seizure counts will be obtained at every visit.
The Quality of Life in Epilepsy-31 Patient Inventory questionnaire will be administered once during the study.
A Medical Resource utilization questionnaire will be used to obtain cost-effectiveness information on carisbamate and will be administered twice during the study.
There is no statistical testing hypothesis for this study.
Carisbamate tablets taken twice daily in 2 equally divided doses, with or without food, and taken with noncarbonated water.
During the first week on study, patients will take blinded transition study medication and thereafter will take a target dosage of 800 mg/day of unblinded, open-label study medication.
The dosage of study medication will range from 400 to 1,200 mg/day.
Patients will receive treatment for 1 year with the potential to receive treatment longer.
Study Type
Interventional
Enrollment (Actual)
403
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have completed the 14-week double-blind treatment phase of study CARISEPY3013
- must be willing/able to follow the restrictions and prohibitions of the protocol
- must be able to complete the patient diaries correctly (patients or legally acceptable representatives)
- must sign an informed consent form indicating agreement to participate in the study (patients or legally acceptable representatives)
- adolescents capable of understanding the nature of the study must provide assent to participate in the study
Exclusion Criteria:
- Patients who have not completed the 14-week double-blind treatment phase of study CARISEPY3013.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 001
placebo placebo for 1 week
|
placebo for 1 week
|
Experimental: 002
carisbamate 400 mg/day to 1,200 mg per day
|
400 mg/day to 1,200 mg per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety will be evaluated by the monitoring of the frequency, severity, and timing of adverse events, clinical laboratory test results, 12-lead electrocardiogram (ECG) recordings, vital signs measurements, physical and neurologic examinations
Time Frame: after a stable dose of Carisbamate is achieved, study visits to assess safety will be every three months for the duration of the subject's participation; subjects will also maintain a seizure count diary
|
after a stable dose of Carisbamate is achieved, study visits to assess safety will be every three months for the duration of the subject's participation; subjects will also maintain a seizure count diary
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the impact of carisbamate on subject functioning and well being using the QOLIE-31 Patient Inventory (as exploratory). Administered at month 3 and end of study.
Time Frame: after a stable dose of Carisbamate is achieved, study visits to assess safety will be every three months for the duration of the subject's participation; subjects will also maintain a seizure count diary
|
after a stable dose of Carisbamate is achieved, study visits to assess safety will be every three months for the duration of the subject's participation; subjects will also maintain a seizure count diary
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
August 1, 2010
Study Completion (Actual)
August 1, 2010
Study Registration Dates
First Submitted
August 29, 2008
First Submitted That Met QC Criteria
August 29, 2008
First Posted (Estimate)
September 1, 2008
Study Record Updates
Last Update Posted (Estimate)
June 18, 2013
Last Update Submitted That Met QC Criteria
June 10, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 333369EPY3014
- CARISEPY3014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy, Complex Partial
-
SK Life Science, Inc.CompletedEpilepsy | Epilepsy, Complex Partial | Seizure Disorder | Complex Partial Seizures | Epilepsy, Focal
-
SK Life Science, Inc.CompletedEpilepsy | Epilepsy, Complex Partial | Seizure Disorder | Complex Partial Seizures | Epilepsy, Focal
-
SK Life Science, Inc.CompletedEpilepsy | Epilepsies, Partial | Epilepsy, Complex Partial | Complex Partial Seizures
-
Northeast Regional Epilepsy GroupPfizerTerminatedEpilepsy, Complex PartialUnited States
-
University of MinnesotaCompleted
-
Supernus Pharmaceuticals, Inc.Melbourne HealthCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedEpilepsy | Epilepsies, Partial | Partial Seizure Disorder | Complex Partial Seizure DisorderCosta Rica, Peru, El Salvador, Guatemala
-
SK Life Science, Inc.CompletedEpilepsy, Complex Partial | Epilepsy, Partial, Motor | Epilepsy, Simple Partial | Focal Motor Epilepsy
-
Marinus PharmaceuticalsCompletedEpilepsy, Complex PartialUnited States
-
National Institute of Neurological Disorders and...CompletedEpilepsy | Epilepsy, Complex PartialUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States